Abstract
Objective: To determine if a direct measure of instrumental activities of daily living (IADL) scale designed for use with dementia patients can detect differences between persons with mild cognitive impairment (MCI) and normal elderly control subjects (NC). Methods: This study used cross-sectional and longitudinal IADL scale data from MCI and NC subjects followed at an Alzheimers Disease Center. Results: On a 52-point scale, MCI subjects (n = 30) scored significantly lower than NC subjects (n = 30) on the IADL scale (total score 47.17 vs. 48.77 points; t (58) = 2.34, p = .011) and its Memory subscale (5.27 vs. 6.6 points; t (58) = 3.29, p = .002).Examination of annualized IADL scale change scores revealed that 50% of MCI subjects had declined by one point, compared with 29% of NC. Conclusion: A direct IADL measure for dementia patients is able to detect small differences between MCI and NC and cross-sectionally and longitudinally, but does not distinguish between groups.
Keywords: Mild cognitive impairment, IADL, Texas Functional Living Scale
Current Alzheimer Research
Title: Can a Direct IADL Measure Detect Deficits in Persons with MCI?
Volume: 6 Issue: 1
Author(s): Dani L. Binegar, Linda S. Hynan, Laura H. Lacritz, Myron F. Weiner and C. Munro Cullum
Affiliation:
Keywords: Mild cognitive impairment, IADL, Texas Functional Living Scale
Abstract: Objective: To determine if a direct measure of instrumental activities of daily living (IADL) scale designed for use with dementia patients can detect differences between persons with mild cognitive impairment (MCI) and normal elderly control subjects (NC). Methods: This study used cross-sectional and longitudinal IADL scale data from MCI and NC subjects followed at an Alzheimers Disease Center. Results: On a 52-point scale, MCI subjects (n = 30) scored significantly lower than NC subjects (n = 30) on the IADL scale (total score 47.17 vs. 48.77 points; t (58) = 2.34, p = .011) and its Memory subscale (5.27 vs. 6.6 points; t (58) = 3.29, p = .002).Examination of annualized IADL scale change scores revealed that 50% of MCI subjects had declined by one point, compared with 29% of NC. Conclusion: A direct IADL measure for dementia patients is able to detect small differences between MCI and NC and cross-sectionally and longitudinally, but does not distinguish between groups.
Export Options
About this article
Cite this article as:
Binegar L. Dani, Hynan S. Linda, Lacritz H. Laura, Weiner F. Myron and Cullum Munro C., Can a Direct IADL Measure Detect Deficits in Persons with MCI?, Current Alzheimer Research 2009; 6 (1) . https://dx.doi.org/10.2174/156720509787313880
DOI https://dx.doi.org/10.2174/156720509787313880 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Homocysteine, Intracellular Signaling and Thrombotic Disorders
Current Medicinal Chemistry Cholinergic System and Neuroinflammation: Implication in Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Plant Polyphenols as Neuroprotective Agents in Parkinson’s Disease Targeting Oxidative Stress
Current Drug Targets Bioactive Fish Fatty Acids: Health Effects and Their Use as Functional Food Ingredients
Current Nutrition & Food Science Neurodegenerative Disorders and Cholesterol
Current Alzheimer Research Editorial (Hot Topic: Platelets in Vascular Homeostasis and Inflammation: Current Perspectives from Bench to Bedside)
Current Vascular Pharmacology The Pelvic Floor During Pregnancy and after Childbirth, and the Effect of Pelvic Floor Muscle Training on Urinary Incontinence - A Literature Review
Current Women`s Health Reviews Applying Epigenetics to Alzheimer’s Disease via the Latent Early–life Associated Regulation (LEARn) Model
Current Alzheimer Research Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry The Phosphoinositide Signal Transduction Pathway in the Pathogenesis of Alzheimer’s Disease
Current Alzheimer Research Insights on the Neuromodulatory Propensity of Selaginella (Sanjeevani) and its Potential Pharmacological Applications
CNS & Neurological Disorders - Drug Targets Nanoneuromedicines for Neurodegenerative Diseases
Nanoscience & Nanotechnology-Asia Association between ALDH2 Gene Polymorphism and Late-onset Alzheimer Disease: An Up-to-date Meta-analysis
Current Alzheimer Research Non-Pharmacological Approaches to the Prevention and Treatment of Alzheimer’s Disease with Respect to the Rising Treatment Costs
Current Alzheimer Research Inhibitors of the 5-Lipoxygenase Pathway in Atherosclerosis
Current Pharmaceutical Design Alzheimers Disease: Interactions Between Cholinergic Functions and β- amyloid
Current Alzheimer Research Minocycline and Cytoprotection: Shedding New Light on a Shadowy Controversy
Current Drug Delivery Alpha-1-Antichymotrypsin: A Common Player for Type 2 Diabetes and Alzheimer's Disease
Current Diabetes Reviews A Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Safety and Tolerability of Two Doses of Divalproex Sodium in Outpatients with Probable Alzheimers Disease
Current Alzheimer Research Histamine H3 Receptor (H3R) Antagonists and Inverse Agonists in the Treatment of Sleep Disorders
Current Pharmaceutical Design